Features of Top Medical Device Companies

ResMed's Mick Farrell: "Our primary competitor is ignorance"

November 25, 2013 by Brian Johnson

ResMed CEO Mick Farrell tells MassDevice.com about the history of ResMed, its sleep apnea devices and the future of treating chronic disease.

The story behind ResMed's (NYSE:RMD) meteoric rise from Baxter spinout to $1.5 billion medical device Goliath is no snore.

Or maybe it is. After all, stopping snoring has paid off pretty nicely for the San Diego-based sleep apnea device company, which has a more than 40% share in the growing market for products to diagnose, treat and manage respiratory disorders.

Restoring sight to the blind: A conversation with Second Sight's Robert Greenberg

November 21, 2013 by Brian Johnson

Dr. Robert Greenberg, founder & CEO of Second Sight Medical, chats with MassDevice.com in advance of his appearance at the Big 100 West to discuss the Argus II 'bionic eye.'

Restoring sight to the blind: Second Sight's Robert Greenberg

Second Sight Medical's Argus II "bionic eye" is likely the most talked-about medical device of 2013.

The retinal prosthesis, approved by the FDA last summer, isn't slated to hit the market until 2014, but the buzz around the device is already at a fever pitch.

MassDevice.com Q&A: Skyline Medical CEO Josh Kornberg

November 20, 2013 by Chris Walker

CEO Josh Kornberg tells MassDevice.com about cleaning house and how bad news for rival Stryker Corp. is helping to reinvigorate Skyline Medical.

MassDevice.com Q&A: Skyline CEO Josh Kornberg

When John Kornberg joined then-BioDrain Medical in 2011 as an investor, the company had spent the past decade developing its Streamway surgical waste management device and getting clearance to commercialize it in the U.S. But, Kornberg told MassDevice.com recently, it was quickly apparent that BioDrain was stalled, unable to leverage its 510(k) clearance from the FDA into significant U.S. sales.

Can Glooko disrupt the way diabetes is managed?

November 7, 2013 by Brian Johnson

In this MassDevice.com podcast, we speak with Glooko CEO Rick Altinger about the company's mobile diabetes management application for smartphones and how it has the potential to change the spectrum of care for one of the world's most common chronic diseases.

Can Glooko disrupt the way diabetes is managed?

Glooko continues to carve out a niche in the mobile diabetes management space.

Deflating the hype: Are we setting renal denervation up for disappointment?

November 1, 2013 by Arezu Sarvestani

Renal denervation has won a lot of praise as a potential solution for patients with resistant hypertension, but the excessive celebration of early clinical trial results may be setting everyone up for a major letdown and a harsh backlash. This week cardiologists at the Transcatheter Cardiovascular Therapeutics conference, including those involved with Medtronic's and Boston Scientific's clinical trials, warned of the dangers of exaggeration.

Deflating the hype: Are we setting renal denervation up for disappointment?

Renal denervation is still in its youth, but the limited clinical trials and lack of substantial confirmation hasn't curbed much of the hype for the technology as a means of treating patients with resistant hypertension.

Diabetes: CeQur CEO Jim Peterson's personal mission to improve the standard of care

October 16, 2013 by Brian Johnson

CeQur CEO Jim Peterson discusses the motivation behind his mission to improve the lives of patients who suffer from Type II diabetes.

Diabetes: CeQur CEO Jim Peterson's personal mission to improve the standard of care

Most people are brought into the medical device industry because of a passion for a specific disease or a personal connection to a condition that's had an impact on his or her life.

For Jim Peterson, the CEO and founder of CeQur, that motivation was right inside his own house. His daughter was diagnosed with Type I diabetes at 3 years old.

Hacking healthcare: Would we know if a medical device was hacked?

August 26, 2013 by Arezu Sarvestani

The absence of reported hacks on medical devices doesn't mean they aren’t happening, experts say, because there are no mechanisms in place to detect them.

How would we know if medical devices had been hacked?

The FDA has made medical device cybersecurity a high priority, even as it stresses that there have been no reported incidents of malicious medical device hacks or of patients harmed by a security-related issue.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

MassDevice.com Q&A: Venaxis CEO Steve Lundy

August 20, 2013 by Sony Salzman

Venaxis CEO Steve Lundy tells MassDevice.com how a rapid blood test to rule out appendicitis can help eliminate unnecessary CT scans in the emergency room.

MassDevice.com Q&A: Venaxis CEO Steve Lundy

Of the 10.5 million cases of abdominal pain that present in American emergency rooms each year, only about 300,000 end up being confirmed as appendicitis. That means an expensive glut of ultimately unnecessary – and potentially cancer-causing – CT scans performed in ERs.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Medical device cybersecurity tools in the real world

August 15, 2013 by Arezu Sarvestani

From rampant hack-ability to risk transparency and hospital budgets, Medical Device Innovation, Safety & Security Consortium co-founder and executive director Dr. Dale Nordenberg tells MassDevice.com how a swath of healthcare industry stakeholders are coming together to build tools to address cybersecurity in medical devices.

New tools allow hospitals to compare medical devices based on their cybersecurity

Regulators and healthcare providers are developing tools and standards to assess medical devices and their digital defenses, as medtech cybersecurity takes some giant steps from the theoretical to the practical.

MassDevice.com Q&A: James Mazzo on his move to Versant Ventures

July 30, 2013 by Brad Perriello

James Mazzo, the former head of Abbott Medical Optics, tells MassDevice.com about his decision to become Versant Ventures' 1st operating partner.

MassDevice.com Q&A: James Mazzo on his move to Versant Ventures

James Mazzo has put 35 years into the optics and ophthalmology business, so it was no surprise that he got involved with AcuFocus and its device for treating presbyopia. Mazzo, who stepped down from leading Abbott Medical Optics earlier this year, added another title to his resume that's more of a departure: He's the 1st "operating partner" at Versant Ventures.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp